-+ 0.00%
-+ 0.00%
-+ 0.00%

Phathom says VOQUEZNA cost-effectiveness model shows drug cost-effective vs PPIs in erosive GERD

PUBT·10/12/2026 12:06:04
Phathom says VOQUEZNA cost-effectiveness model shows drug cost-effective vs PPIs in erosive GERD
  • Phathom Pharmaceuticals flagged new VOQUEZNA cost-effectiveness results already presented at ACG 2026 in Nashville, October 9-14.
  • A lifetime economic model indicated VOQUEZNA could be cost-effective versus PPIs in erosive GERD, with potential net-price savings.
  • The analysis also projected fewer long-term GERD complications versus PPIs, supporting a broader value proposition beyond symptom control.
  • Additional ACG 2026 presentations included BMI-subgroup results in non-erosive GERD, showing consistent benefit across body-weight categories.
  • Real-world data showed VOQUEZNA starters had more severe baseline disease than prescription PPI starters, signaling early use in harder-to-treat patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120800PRIMZONEFULLFEED9843809) on October 12, 2026, and is solely responsible for the information contained therein.